Adjunctive Molecular Hydrogen Capsule Therapy in Empyema Complicated by Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report

Abstract

Background/Aim: The management of Stage II empyema complicated by chronic inflammatory demyelinating polyneuropathy (CIDP) presents a formidable clinical challenge due to the precarious balance required between aggressive infection control and the modulation of immune-mediated neurological frailty. We report a complex case of comorbid empyema and CIDP successfully managed with a multidisciplinary approach and adjuvant molecular Case Report: A 76-year-old male with CIDP presented with acute respiratory failure secondary to Stage II empyema. Following video-assisted thoracoscopic surgery (VATS) decortication, the patient exhibited systemic hyperinflammation and immune exhaustion. Adjuvant oral molecular hydrogen therapy was initiated during the critical phase. Longitudinal